Cello Health PLC Director/PDMR Shareholding (9198F)
October 31 2018 - 11:30AM
UK Regulatory
TIDMCLL
RNS Number : 9198F
Cello Health PLC
31 October 2018
31 October 2018
Cello Health plc
("Cello" or the "Group")
Director/PDMR Shareholding
The Group notifies that, on 31 October 2018, Mark Scott, Chief
Executive of the Company, purchased 10,000 ordinary shares of 10
pence each in the capital of the Company ("Ordinary Shares") for a
price of 113 pence per share.
Following the above purchase, Mr Scott holds 1,465,475 Ordinary
Shares, representing approximately 1.39% of the Company's issued
ordinary share capital.
Enquiries:
Cello Health plc 020 7812 8460
Mark Scott, Chief Executive
Mark Bentley, Finance Director
Cenkos Securities plc 0207 397 8900
Mark Connelly
Harry Hargreaves
Notes to Editors
Cello Health plc is a global healthcare-focused advisory Group
comprised of a set of leading clinical, commercial advisory and
digital delivery capabilities. Cello Health plc currently services
24 of the top 25 pharmaceutical clients globally, as well as a wide
range of biotech, diagnostics, devices and other key non-healthcare
clients.
Cello Health plc enables clients to commercialise, differentiate
their assets, and drive brand success in ever more complex global
markets. The business delivers its services through nearly 1,000
highly skilled professionals, utilising latest thinking, technology
and digital solutions.
Cello Health plc delivers its services from an office network in
the UK, USA, and Asia, with hub offices in New York City,
Philadelphia PA, London, Edinburgh, Farnham and Cheltenham.
For further information, please visit:
https://cellohealthplc.com
Template for notification and public disclosure of transactions
by persons discharging managerial responsibilities and persons
closely associated with them
1 Details of the person discharging managerial responsibilities
/ person closely associated
a) Name Mark Scott
-------------------------------------- ---------------------------------------
2 Reason for the notification
-------------------------------------------------------------------------------
a) Position/status Chief Executive
-------------------------------------- ---------------------------------------
b) Initial notification Initial notification
/Amendment
-------------------------------------- ---------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
-------------------------------------------------------------------------------
a) Name Cello Health plc
-------------------------------------- ---------------------------------------
b) LEI 2138004TZYGZLWQP7N64
-------------------------------------- ---------------------------------------
4 Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions
have been conducted
-------------------------------------------------------------------------------
a) Description of the Ordinary shares of 10 pence each
financial instrument,
type of instrument
Identification code ISIN: GB00B0310763
-------------------------------------- ---------------------------------------
b) Nature of the transaction Purchase of ordinary shares
-------------------------------------- ---------------------------------------
c) Price(s) and volume(s)
------------------ ----------------
Price(s) Volume(s)
------------------ ----------------
113 pence 10,000
-------------------------------------------------------------- ----------------
d) Aggregated information
- Aggregated volume 10,000
- Price GBP11,300.00
-------------------------------------- --------------------------------------------
e) Date of the transaction 31 October 2018
-------------------------------------- ---------------------------------------
f) Place of the transaction AIMX
-------------------------------------- ---------------------------------------
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
DSHFKDDDPBDDFKN
(END) Dow Jones Newswires
October 31, 2018 11:30 ET (15:30 GMT)
Cello Health (LSE:CLL)
Historical Stock Chart
From Jul 2024 to Aug 2024
Cello Health (LSE:CLL)
Historical Stock Chart
From Aug 2023 to Aug 2024